A panel of experts in urology and urogynecology share their experiences in caring for patients with overactive bladder (OAB) from initial diagnosis to treatment and management of the disease.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.